<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hereditary kidney cancer syndromes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hereditary kidney cancer syndromes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hereditary kidney cancer syndromes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Toni K Choueiri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian Shuch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary kidney cancer syndromes were initially described based on clinical observations that defined the disease phenotype. Family studies and advances in molecular genetics have provided important insights into the molecular pathways underlying the pathogenesis of these syndromes, as well as new insights into sporadic renal cell carcinoma (RCC) [
         <a href="#rid1">
          1,2
         </a>
         ]. Each of these syndromes has its own molecular alteration, and these are often reflected in distinctive histologic features and clinical course.
        </p>
        <p>
         The inherited kidney cancer syndromes are presented here  (
         <a class="graphic graphic_table graphicRef53600" href="/z/d/graphic/53600.html" rel="external">
          table 1
         </a>
         ). Other topics related to the diagnosis and management RCC are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2961.html" rel="external">
          "Prognostic factors in patients with renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">
          "Overview of the treatment of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2121494423">
         <span class="h1">
          ESTABLISHING THE DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among all cases of renal cell carcinoma (RCC), approximately five percent or less are due to a hereditary syndrome [
         <a href="#rid3">
          3,4
         </a>
         ]. Observational studies of patients with RCC undergoing tumor sequencing have confirmed the low incidence of highly penetrant pathogenic variants that cause kidney cancer [
         <a href="#rid5">
          5
         </a>
         ]. By contrast, individuals with high-risk clinical features or a family history suggestive of a hereditary kidney cancer syndrome may have a higher incidence of a germline pathogenic variant.
        </p>
        <p>
         As such, the most important step in establishing the diagnosis of a hereditary kidney cancer syndrome is recognizing the associated clinical features, as described in this topic. These initial clinical features, along with the patient's family history, are effective means for identifying affected individuals who should undergo further evaluation for hereditary kidney cancer syndromes [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The identification of an inherited genetic predisposition for renal cell carcinoma in a patient or family member may be an indication for screening for cancer or dictate a treatment strategy that can minimize or prevent disease-related morbidity [
         <a href="#rid6">
          6
         </a>
         ]. Discussions about the risks and benefits of genetic screening for a hereditary kidney cancer syndrome should involve a trained genetic counselor who can review any issues with patients prior to proceeding with genetic testing. (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         .)
        </p>
        <p>
         Further details on genetic counseling for patients with a suspected hereditary kidney cancer syndrome are discussed separately  (
         <a class="graphic graphic_table graphicRef116271" href="/z/d/graphic/116271.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">
          "Diagnostic approach, differential diagnosis, and management of a small renal mass", section on 'Genetic counseling'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H626544775">
         <span class="h1">
          POLYCYSTIC KIDNEY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autosomal dominant polycystic kidney disease is a common disorder, occurring in approximately 1 in every 400 to 1000 live births. It is estimated that fewer than one-half of these cases are diagnosed during an individual's lifetime, since the disease is often clinically silent. (See
         <a class="medical medical_review" href="/z/d/html/1682.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1680.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Kidney manifestations", section on 'Renal cancer'
         </a>
         .)
        </p>
        <p>
         The incidence of renal cell carcinoma (RCC) in patients with polycystic kidney disease does not appear to be increased compared with the general population [
         <a href="#rid7">
          7,8
         </a>
         ]. However, compared to patients with sporadic RCC in the general population, patients with polycystic kidney disease who develop RCC have tumors that are more often bilateral (12 versus 1 to 4 percent), multicentric (28 versus 6 percent), and of sarcomatoid histology (33 versus 1 to 5 percent).
        </p>
        <p>
         A subset of patients with autosomal dominant polycystic kidney disease may also have features of tuberous sclerosis complex (TSC). This condition is known as
         <em>
          TSC2
         </em>
         /
         <em>
          PKD1
         </em>
         contiguous gene syndrome, since the polycystic kidney disease 1 (
         <em>
          PKD1
         </em>
         ) gene is located adjacent to the TSC2 gene [
         <a href="#rid9">
          9
         </a>
         ] It is unknown whether patients with this condition are at higher risk of kidney cancer.
         <em>
          TSC2
         </em>
         /
         <em>
          PKD1
         </em>
         contiguous gene syndrome is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'TSC2/PKD1 contiguous gene syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HEREDITARY PAPILLARY RENAL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary papillary renal carcinoma (HPRC) is a familial cancer syndrome in which affected individuals are at risk for the development of papillary renal cell carcinomas [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Papillary carcinomas'
         </a>
         .)
        </p>
        <p>
         HPRC is a highly penetrant, autosomal dominant condition. Both early and late-onset forms of HPRC have been described [
         <a href="#rid11">
          11,12
         </a>
         ]. HPRC is manifested primarily by the development of papillary renal tumors, which are often multifocal and bilateral. On imaging studies, the lesions are relatively hypovascular and grow slowly [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Genetic linkage analyses found that the
         <em>
          HPRC
         </em>
         gene (the c-
         <em>
          MET
         </em>
         protooncogene) is located on the long arm of chromosome 7 [
         <a href="#rid14">
          14
         </a>
         ]. This gene codes for a membrane-bound receptor for hepatocyte growth factor (HGF) and has an intracellular tyrosine kinase domain. Pathogenic variants in
         <em>
          MET
         </em>
         constitutively activate the tyrosine kinase domain of this protein in patients with HPRC [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Most patients have bilateral, multifocal tumors. As such, nephron-sparing procedures such as partial nephrectomy are preferred to maintain renal function while minimizing the risk of distant metastases [
         <a href="#rid16">
          16
         </a>
         ]. Patients with smaller kidney tumors are generally managed with active surveillance. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">
          "Diagnostic approach, differential diagnosis, and management of a small renal mass", section on 'Active surveillance'
         </a>
         .)
        </p>
        <p>
         The treatment of patients with distant metastases or unresectable disease, including agents targeting the
         <em>
          MET
         </em>
         pathway, is being discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma", section on 'Papillary renal cell carcinoma'
         </a>
         .)
        </p>
        <p>
         Analysis of germline
         <em>
          MET
         </em>
         pathogenic variants is recommended for patients with clinical features that raise suspicion for a diagnosis of HPRC, such as bilateral, multifocal, or familial papillary renal cell carcinoma.
        </p>
        <p class="headingAnchor" id="H2142544">
         <span class="h1">
          KIDNEY CANCER ASSOCIATED WITH GERMLINE PATHOGENIC VARIANTS OF THE TRICARBOXYLIC ACID CYCLE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inherited pathogenic variants involving enzymes of the tricarboxylic acid (Krebs) cycle are associated with aggressive forms of renal cell carcinoma (RCC) that have a propensity to metastasize even at a small size. Therefore, early surgical intervention is warranted, even for very small tumors.
        </p>
        <p>
         Enzymes with alterations contributing to RCC include fumarate hydratase, which causes hereditary leiomyomatosis and RCC, and succinate dehydrogenase, which is associated with hereditary paraganglioma and pheochromocytoma, gastrointestinal stomal tumors (GIST), and rarely, RCC. (See
         <a class="medical medical_review" href="/z/d/html/130.html" rel="external">
          "Clinical presentation and diagnosis of pheochromocytoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">
          "Pheochromocytoma and paraganglioma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'SDH-deficient tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hereditary leiomyomatosis and renal cell cancer syndrome
         </span>
        </p>
        <p class="headingAnchor" id="H1715850812">
         <span class="h3">
          Molecular pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome in which affected family members have cutaneous and uterine leiomyomas, and/or RCCs that resemble high-grade papillary RCC (also known as fumarate-hydratase deficient renal cell carcinoma). This syndrome was previously known as multiple cutaneous and uterine leiomyomatosis syndrome (MCUL1) or Reed's syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Fumarate hydratase-deficient RCC and hereditary leiomyomatosis and renal cell cancer associated RCC'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15676.html" rel="external">
          "Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential", section on 'Fumarate hydratase deficiency'
         </a>
         .)
        </p>
        <p>
         Family studies have linked HLRCC to molecular alterations in the fumarate hydratase (
         <em>
          FH
         </em>
         ) gene, which is located on the long arm of chromosome 1 [
         <a href="#rid17">
          17
         </a>
         ].
         <em>
          FH
         </em>
         is part of the mitochondrial Krebs or tricarboxylic acid cycle. There are several mechanisms by which alterations in
         <em>
          FH
         </em>
         leads to tumorigenesis, including increased cellular dependence on glycolysis and pseudohypoxia and fumarate serving as an oncometabolite to damage various repair subcellular processes like DNA repair [
         <a href="#rid18">
          18-20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">
          "Molecular biology and pathogenesis of von Hippel-Lindau disease", section on 'Hypoxia-inducible factor 1 and 2'
         </a>
         .)
        </p>
        <p>
         HLRCC is transmitted in an autosomal dominant fashion, and the
         <em>
          FH
         </em>
         gene is thought to act as a tumor suppressor gene. Germline alterations that have been identified include missense, nonsense, insertion, deletion, and splice-site mutations [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3170497420">
         <span class="h3">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         One clinical feature of the disease is the occurrence of severely symptomatic uterine fibroids among affected women, often requiring hysterectomy at a young age due to uterine bleeding or discomfort [
         <a href="#rid22">
          22
         </a>
         ]. Leiomyomas to leiomyosarcomas have been reported in individuals with HLRCC [
         <a href="#rid23">
          23
         </a>
         ], but it is unclear whether this is due to atypical pathologic features or occurred spontaneously.
        </p>
        <p>
         Cutaneous leiomyomas are common among individuals with HLRCC. These leiomyomas typically develop on the trunk and extremities and are quite apparent and symptomatic. Often patients found incidentally may have only subtle skin findings [
         <a href="#rid22">
          22,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">
          "Hereditary leiomyomatosis and renal cell cancer (HLRCC)", section on 'Cutaneous leiomyomas'
         </a>
         .)
        </p>
        <p>
         Among patients with HLRCC, although the incidence of renal cell carcinoma is between 20 to 30 percent [
         <a href="#rid17">
          17,24
         </a>
         ], the lifetime penetrance is estimated at less than 10 percent [
         <a href="#rid25">
          25,26
         </a>
         ]. Renal tumors tend to be aggressive, with rapid nodal and distant dissemination, even if the primary kidney tumor is relatively small and contained. As an example, in a French series of 182 patients with HLRCC, the median age at diagnosis was 40 years old, and 82 percent had metastatic disease at diagnosis [
         <a href="#rid27">
          27
         </a>
         ]. Due to the limited treatment options at the time, the median survival in those with metastatic disease was 18 months.
        </p>
        <p class="headingAnchor" id="H2704281383">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HLRCC syndrome should undergo regular surveillance imaging for renal carcinoma with magnetic resonance imaging (MRI), with early intervention upon diagnosis. Details on surveillance are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">
          "Hereditary leiomyomatosis and renal cell cancer (HLRCC)", section on 'Surveillance for renal cancer'
         </a>
         .)
        </p>
        <p>
         A multidisciplinary approach is required for optimal management of patients with HLRCC, including referrals, when indicated, to gynecology, dermatology, urology, medical oncology, and genetic counseling.
        </p>
        <p>
         Patients with HLRCC and locally advanced RCC should be offered prompt surgical management with wide surgical margins and consideration of retroperitoneal lymph node dissection, due to the high risk of metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15516.html" rel="external">
          "Hereditary leiomyomatosis and renal cell cancer (HLRCC)", section on 'Surveillance for renal cancer'
         </a>
         .)
        </p>
        <p>
         For patients with HLRCC and unresectable or metastatic RCC, we suggest
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         rather than other systemic agents. Systemic targeted therapy with bevacizumab and erlotinib has demonstrated particular efficacy in patients with HLRCC [
         <a href="#rid28">
          28,29
         </a>
         ]. In patients with HLRCC, tumorigenesis is driven by genetic alterations to glucose metabolism [
         <a href="#rid17">
          17-19,30,31
         </a>
         ]. The combination of bevacizumab and erlotinib (inhibitors of vascular endothelial growth factor [VEGF] and epidermal growth factor receptor [EGFR], respectively) is hypothesized to inhibit effective glucose delivery to tumor cells, presenting a logical therapeutic approach to this disease [
         <a href="#rid30">
          30
         </a>
         ]. Further studies are needed to confirm the efficacy and toxicity of this approach.
        </p>
        <p>
         In preliminary results from a nonrandomized phase II trial, among all 83 patients with advanced papillary RCC treated with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         , the objective response rate (ORR) was 54 percent [
         <a href="#rid28">
          28
         </a>
         ]. The ORR was higher among the 43 patients with HLRCC compared to the 40 patients with sporadic papillary RCC (72 versus 35 percent, respectively), and was independent of International Metastatic RCC Database Consortium (IMDC) risk group  (
         <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">
          table 3
         </a>
         ) or prior therapy. For patients with HLRCC, median progression-free survival (PFS) was approximately 21 months. (See
         <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">
          "The treatment of advanced non-clear cell renal carcinoma", section on 'Papillary renal cell carcinoma'
         </a>
         .)
        </p>
        <p>
         Data are limited and have mixed results for the efficacy of checkpoint inhibitor immunotherapy in patients with HLRCC. While one case report showed no responders to checkpoint inhibitor therapy among eight treated patients with metastatic HLRCC [
         <a href="#rid32">
          32
         </a>
         ], another case report demonstrated a complete response to the combination of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         and
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2142734">
         <span class="h2">
          Succinate dehydrogenase deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) is comprised of four subunits (
         <em>
          SDHA
         </em>
         ,
         <em>
          SDHB
         </em>
         ,
         <em>
          SDHC
         </em>
         , and
         <em>
          SDHD
         </em>
         ) and an assembly factor (
         <em>
          SDHAF2)
         </em>
         . Mutations of each component have been associated with cases of RCC [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Succinate dehydrogenase-deficient renal cell carcinoma is a rare, aggressive variant of RCC [
         <a href="#rid35">
          35
         </a>
         ].
         <em>
          SDH
         </em>
         -associated RCC presents at an early age [
         <a href="#rid34">
          34
         </a>
         ], although the age at diagnosis ranges from 24 to 73 years [
         <a href="#rid36">
          36,37
         </a>
         ]. The histologic type of kidney cancer varies, perhaps by altered subtype, but cases have been observed with clear cell, papillary, chromophobe, and an eosinophilic RCC [
         <a href="#rid36">
          36-38
         </a>
         ]. Studies of metastatic
         <em>
          SDH
         </em>
         -associated RCC have reported treatment response to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         or
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Succinate dehydrogenase–deficient renal cell carcinoma'
         </a>
         .)
        </p>
        <p>
         This enzyme deficiency is also associated with an autosomal dominant condition called hereditary paraganglioma and pheochromocytoma. The syndrome is characterized by paragangliomas involving the head and neck region, thorax, abdomen, pelvis, and/or urinary bladder. Paragangliomas typically develop in patients in their thirties. (See
         <a class="medical medical_review" href="/z/d/html/133.html" rel="external">
          "Pheochromocytoma in genetic disorders"
         </a>
         .)
        </p>
        <p>
         Testing for pathogenic variants in
         <em>
          SDH
         </em>
         is advised in patients with early onset kidney cancer (ie, age &lt;45 years), bilateral or multifocal tumors, pathologic or immunohistochemical findings that suggest loss of
         <em>
          SDH
         </em>
         , or a personal or family history of pheochromocytoma or paraganglioma, gastrointestinal stromal tumors, and/or kidney cancer [
         <a href="#rid6">
          6,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/130.html" rel="external">
          "Clinical presentation and diagnosis of pheochromocytoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">
          "Pheochromocytoma and paraganglioma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'SDH-deficient tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          BIRT-HOGG-DUBÉ SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Birt-Hogg-Dubé (BHD) syndrome is an inherited syndrome in which affected individuals are at risk for the development of bilateral, multifocal kidney cancer, as well as various dermatologic and pulmonary lesions [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/100661.html" rel="external">
          "Birt-Hogg-Dubé syndrome"
         </a>
         .)
        </p>
        <p>
         BHD syndrome is caused by pathogenic variants in the folliculin (
         <em>
          FLCN
         </em>
         ) gene (also known as the BHD gene), which is localized to the short arm of chromosome 17 [
         <a href="#rid42">
          42,43
         </a>
         ]. Pathogenic variants in the germline of affected individuals have been identified in 90 percent of affected families [
         <a href="#rid44">
          44
         </a>
         ]. DNA sequencing of renal tumors from patients with germline
         <em>
          FLCN
         </em>
         pathogenic variants has identified somatic pathogenic variants in the wild-type copy of the gene, suggesting that
         <em>
          FLCN
         </em>
         is a loss-of-function tumor suppressor gene [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         The
         <em>
          FLCN
         </em>
         gene may be involved in energy, metabolism, and nutrient sensing through the mammalian target of rapamycin (mTOR) pathway. The folliculin-interacting protein (FNIP1) interacts with 5' AMP-activated protein kinase (AMPK), a key molecule for energy sensing to negatively regulate mTOR activity [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         The penetrance of renal cancer in patients with BHD is up to 30 percent [
         <a href="#rid47">
          47,48
         </a>
         ]. In one series, the risk of renal tumors was 27 percent at a mean age of 50 years [
         <a href="#rid47">
          47
         </a>
         ]. However, the incidence of renal tumors may vary in different families, and BHD may be underdiagnosed in patients with variable skin findings. One series that included 115
         <em>
          FLCN
         </em>
         carriers estimated penetrance for renal cancer and pneumothorax to be 16 and 29 percent, respectively, at 70 years of age [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         The histology of renal tumors is variable in patients with BHD syndrome. Tumors typically contain a hybrid of oncocytic and chromophobe renal tumors, but other histologies such as classic chromophobe, oncocytomas, and papillary RCC may be present [
         <a href="#rid41">
          41,47
         </a>
         ].
        </p>
        <p>
         Dermatologic manifestations of BHD syndrome include skin lesions called fibrofolliculomas, which are benign hamartomatous tumors of hair follicles [
         <a href="#rid41">
          41
         </a>
         ]. These whitish papules are most common on the nose and cheeks, and typically are first observed around age 20 years.
        </p>
        <p>
         Approximately 80 percent of patients with BHD have multiple pulmonary cysts that can be identified by computed tomography (CT) of the lungs [
         <a href="#rid41">
          41
         </a>
         ]. Spontaneous pneumothorax may be seen in up to one-fourth of patients [
         <a href="#rid49">
          49-51
         </a>
         ].
        </p>
        <p>
         The kidney cancers observed in patients with BHD syndrome tend to be bilateral or multifocal in more than one-half of cases and are usually slow growing. Thus, the recommended management approach includes observation of tumors less than 3 cm; when surgery is recommended, all visible tumors should be removed [
         <a href="#rid52">
          52
         </a>
         ]. As with hereditary papillary renal carcinoma, nephron-sparing surgery is preferred to radical nephrectomy [
         <a href="#rid41">
          41,53
         </a>
         ]. Follow-up in patients undergoing nephron-sparing surgery is important given the high risk of disease recurrence in the ipsilateral kidney.
        </p>
        <p>
         An animal model of BHD has been developed to provide a model for the evaluation of therapeutic approaches to this syndrome [
         <a href="#rid54">
          54
         </a>
         ]. In this model, treatment with the mTOR inhibitor rapamycin led to tumor shrinkage.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          TUBEROUS SCLEROSIS COMPLEX
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberous sclerosis complex (TSC; also called tuberous sclerosis) is a hereditary condition that is due to pathogenic variants in one of two interacting tumor suppressor gene products, hamartin (TSC1) or tuberin (TSC2). The clinical manifestations include bilateral, multifocal renal lesions, which typically are angiomyolipomas. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features"
         </a>
         .)
        </p>
        <p>
         The predominant management issue for patients with TSC is the risk of growth and bleeding from renal angiomyolipoma. These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'Angiomyolipomas'
         </a>
         .)
        </p>
        <p>
         Fewer than 5 percent of patients with TSC develop renal cell carcinoma [
         <a href="#rid55">
          55
         </a>
         ]. In one observational series, the TSC-associated RCC tumors occurred at a younger age than sporadic tumors and occurred primarily in women [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Tumors can display a wide variety of histologic patterns, such as clear cell, papillary, and chromophobe RCC, as well as those with eosinophilic/oncocytic features (known as low-grade oncocytic [LOT]) [
         <a href="#rid57">
          57
         </a>
         ]. These tumors can present aggressively, especially in patients with clear cell histology [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          OTHER CLEAR CELL RCC HEREDITARY SYNDROMES
         </span>
        </p>
        <p class="headingAnchor" id="H499855826">
         <span class="h2">
          Von Hippel-Lindau disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors, including clear cell carcinoma of the kidney. The pathogenesis of VHL syndrome and the management of patients with VHL are discussed separately. Familial, non-VHL, clear cell renal cell carcinoma (RCC) may also be associated with chromosome 3 translocations [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">
          "Molecular biology and pathogenesis of von Hippel-Lindau disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Von Hippel-Lindau gene'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2581704949">
         <span class="h2">
          Hereditary BAP-1-associated renal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         A germline pathogenic variant in the breast cancer susceptibility 1 (
         <em>
          BRCA1
         </em>
         )-associated protein 1 (
         <em>
          BAP1
         </em>
         ) gene predisposes to familial clear cell RCC [
         <a href="#rid4">
          4,59
         </a>
         ]. Further details about this syndrome are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'BAP1 gene'
         </a>
         .)
        </p>
        <p>
         Other tumors associated with
         <em>
          BAP1
         </em>
         germline pathogenic variants include familial uveal melanoma, cutaneous melanoma and atypical Spitz tumors, and mesothelioma [
         <a href="#rid60">
          60
         </a>
         ]. There is some evidence that meningioma and cholangiocarcinoma may also be linked to
         <em>
          BAP1
         </em>
         pathogenic variants [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">
          "Inherited susceptibility to melanoma", section on 'BAP1 gene'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2504.html" rel="external">
          "Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Inherited susceptibility'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1611474161">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the diagnosis –
         </strong>
         The most important step in establishing the diagnosis of a hereditary kidney cancer syndrome is recognizing the associated clinical features. These initial clinical features, along with the patient's family history, are effective means for identifying affected individuals who should undergo further evaluation for hereditary kidney cancer syndromes. (See
         <a class="local">
          'Establishing the diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening for cancer and genetic testing –
         </strong>
         The identification of an inherited genetic predisposition for renal cell carcinoma in a patient or family member may be an indication for screening for cancer or dictate a treatment strategy that can minimize or prevent disease-related morbidity. Discussions about the risks and benefits of genetic screening should involve a trained genetic counselor who can review any issues with patients prior to proceeding with genetic testing. (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary kidney cancer syndromes –
         </strong>
         The hereditary kidney cancer syndromes are as follows  (
         <a class="graphic graphic_table graphicRef53600" href="/z/d/graphic/53600.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Polycystic kidney disease –
         </strong>
         For patients with polycystic kidney disease who develop renal cell carcinoma (RCC), tumors are more often bilateral, multicentric, and of sarcomatoid histology at presentation compared to those who develop sporadic RCC in the general population. (See
         <a class="local">
          'Polycystic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hereditary papillary renal cell carcinoma
         </strong>
         <strong>
          –
         </strong>
         Hereditary papillary renal carcinoma (HPRC) is an autosomal dominant cancer syndrome associated with pathogenic variants in the
         <em>
          HPRC
         </em>
         (
         <em>
          MET
         </em>
         ) gene. HPRC manifests with multifocal and bilateral papillary renal tumors. (See
         <a class="local">
          'Hereditary papillary renal carcinoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hereditary leiomyomatosis and renal cell cancer –
         </strong>
         Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a syndrome linked to molecular alterations in the fumarate hydratase (
         <em>
          FH
         </em>
         ) gene. HLRCC is associated with fumarate-hydratase deficient renal cell carcinoma, a papillary variant of RCC. (See
         <a class="local">
          'Hereditary leiomyomatosis and renal cell cancer syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Treatment of unresectable or metastatic RCC
         </strong>
         – For patients with HLRCC and unresectable or metastatic renal cell carcinoma, we suggest
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         rather than other systemic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other syndromes –
         </strong>
         Other genetic syndromes associated with hereditary RCC include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Succinate dehydrogenase-deficiency
         </strong>
         – (See
         <a class="local">
          'Succinate dehydrogenase deficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Birt-Hogg-Dube syndrome
         </strong>
         – (See
         <a class="local">
          'Birt-Hogg-Dubé syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Tuberous sclerosis complex
         </strong>
         – (See
         <a class="local">
          'Tuberous sclerosis complex'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Von Hippel-Lindau disease
         </strong>
         – (See
         <a class="local">
          'Von Hippel-Lindau disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pathogenic variants in the breast cancer susceptibility 1 (
         </strong>
         <strong>
          <em>
           BRCA1
          </em>
         </strong>
         <strong>
          )-associated protein 1 (
         </strong>
         <strong>
          <em>
           BAP1
          </em>
         </strong>
         <strong>
          ) gene
         </strong>
         – (See
         <a class="local">
          'Hereditary BAP-1-associated renal cell carcinoma'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hwang JJ, Uchio EM, Linehan WM, Walther MM. Hereditary kidney cancer. Urol Clin North Am 2003; 30:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med 2017; 376:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zbar B, Glenn G, Merino M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 2007; 177:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlo MI, Mukherjee S, Mandelker D, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol 2018; 4:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yngvadottir B, Andreou A, Bassaganyas L, et al. Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Hum Mol Genet 2022; 31:3001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bratslavsky G, Mendhiratta N, Daneshvar M, et al. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer 2021; 127:3957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keith DS, Torres VE, King BF, et al. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 4:1661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta S, Lohse CM, Rowsey R, et al. Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. Eur Urol 2022; 81:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994; 151:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004; 4:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004; 172:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 2002; 178:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998; 58:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001; 165:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001; 68:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005; 205:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudarshan S, Pinto PA, Neckers L, Linehan WM. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 2007; 4:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulkowski PL, Sundaram RK, Oeck S, et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 2018; 50:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int J Cancer 2006; 119:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuch B, Li S, Risch H, et al. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer 2020; 126:3657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014; 13:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller M, Ferlicot S, Guillaud-Bataille M, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Clin Genet 2017; 92:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan R, Gurram S, al Harthy M, et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol 2020; 38:5004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi Y, Keam B, Kim M, et al. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. Cancer Res Treat 2019; 51:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan R, Su D, Stamatakis L, et al. Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib. Eur J Cancer 2014; 50:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 2018; 36:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleeson JP, Nikolovski I, Dinatale R, et al. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res 2021; 27:2910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iribe Y, Furuya M, Shibata Y, et al. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. Fam Cancer 2021; 20:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012; 188:2063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2022; 82:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004; 74:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008; 100:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 2011; 35:1578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuch B, Agochukwu N, Ricketts CJ, et al. Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. J Clin Oncol 2016; 34:e76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paik JY, Toon CW, Benn DE, et al. Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol 2014; 32:e10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009; 10:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002; 2:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasumi H, Baba M, Hasumi Y, et al. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome. Int J Urol 2016; 23:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 2005; 76:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 2005; 97:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006; 103:15552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2002; 26:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houweling AC, Gijezen LM, Jonker MA, et al. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 2011; 105:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med 2007; 175:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977; 113:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welsch MJ, Krunic A, Medenica MM. Birt-Hogg-Dubé Syndrome. Int J Dermatol 2005; 44:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005; 173:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrisford GW, Singer EA, Rosner IL, et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011; 2011:658767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol 2008; 180:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henske EP, Cornejo KM, Wu CL. Renal Cell Carcinoma in Tuberous Sclerosis Complex. Genes (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res 2008; 14:5925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013; 11:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaton JC, Huser H, Blatt Y, Pecht I. Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide. Biochemistry 1975; 14:5308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst 2018; 110:1328.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2948 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14680318" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hereditary kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28121507" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Systemic Therapy for Metastatic Renal-Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17222609" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29978187" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35441217" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34343338" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8011975" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Renal cell carcinoma in autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9853456" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34876325" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complex-associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8308957" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hereditary papillary renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579033" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hereditary papillary renal carcinoma type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15371818" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11804895" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140397" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9563489" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176466" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283798" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15586379" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17287871" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30013182" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865300" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12772087" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16477632" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15937070" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32413184" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25012257" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28300276" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30913859" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29680948" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33658299" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32666341" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23083876" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35853783" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14685938" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18728283" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Germline SDHB mutations and familial renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21934479" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Renal tumors associated with germline SDHB mutation show distinctive morphology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25024072" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24395865" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19959076" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Birt-Hogg-Dubésyndrome: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204536" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26608100" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Birt-Hogg-Dubésyndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15852235" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956655" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17028174" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12459621" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Renal tumors in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22146830" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renal cancer and pneumothorax risk in Birt-Hogg-Dubésyndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17322109" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/596896" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16101870" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Birt-Hogg-DubéSyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821464" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Evaluation and management of renal tumors in the Birt-Hogg-Dubésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22312516" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Familial renal cancer: molecular genetics and surgical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182616" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635231" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8863669" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34680979" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renal Cell Carcinoma in Tuberous Sclerosis Complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794106" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23709298" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/50" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Circular dichroism and fluorescence studies of homogeneous antibodies to type III pneumococcal polysaccharide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30517737" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
